Search

Search Constraints

You searched for: Author/Creator Escher, J

Search Results

1. DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn's disease: interim results of the CAPE registry. (16th January 2018)

2. DOP67 First-line infliximab is cost-effective compared to conventional treatment in paediatric Crohn's Disease – Results from the TISKids study. (21st January 2022)

3. P012 Low frequencies of circulating inhibitory TIGIT+CD38+ effector T cells identify an immunologically distinct subgroup of pediatric patients with severe Crohn's disease. (27th May 2021)

4. P021 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course. (27th May 2021)

5. P095 Consequences of an IL2RA locus duplication in a very early onset inflammatory bowel disease patient. (16th January 2018)

6. P110 TIGIT expression identifies circulating CD38+ effector T cells with immune regulatory properties whose frequencies at diagnosis predict disease course of paediatric IBD patients. (16th January 2018)

7. P205 Prevalence and risk factors for anxiety and depressive symptoms in children, adolescents and young adults with inflammatory bowel disease. (16th January 2018)

9. P398 Effect of Intravenous versus Oral Iron Therapy on Physical Fitness and Haemoglobin in Paediatric IBD Patients with Anaemia. (27th May 2021)